Disease · MONDO_0007027
Comparisons in its trials61
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 61
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 120 mg Elafibranor vs Placebo: deaths from any cause | 6 of 1,437 | 3 of 720 | 2,157 | NCT02704403 | Trial comparisons |
| 120 mg Elafibranor vs Placebo: serious adverse events | 190 of 1,433 | 95 of 717 | 2,150 | NCT02704403 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: deaths from any cause | 6 of 1,185 | 2 of 593 | 1,778 | NCT03028740 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: serious adverse events | 159 of 1,180 | 70 of 589 | 1,769 | NCT03028740 | Trial comparisons |
| 120 mg Elafibranor vs Placebo: Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage | 176 of 717 | 79 of 353 | 1,070 | NCT02704403 | Trial comparisons |
| 120 mg Elafibranor vs Placebo: Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis | 138 of 717 | 52 of 353 | 1,070 | NCT02704403 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 1 | 11 of 145 | 8 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular Ballooning and no Concurrent Worsening of Fibrosis at Year 1 | 23 of 145 | 27 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 7 of 145 | 4 of 144 | 289 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 29 of 145 | 15 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-Point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1 | 22 of 144 | 24 of 143 | 287 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2 | 20 of 215 | 6 of 72 | 287 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2 | 9 of 215 | 1 of 72 | 287 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1 | 6 of 144 | 7 of 143 | 287 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Hepatic Histological Improvement in NAS at Year 2 | 24 of 215 | 7 of 72 | 287 | NCT02217475 | Trial comparisons |
| Obeticholic Acid vs Placebo: serious adverse events | 13 of 141 | 10 of 142 | 283 | NCT01265498 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 2 | 27 of 178 | 8 of 57 | 235 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 2 | 11 of 178 | 3 of 57 | 235 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 2 | 5 of 178 | 2 of 57 | 235 | NCT02217475 | Trial comparisons |
| Obeticholic Acid vs Placebo: Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) | 50 of 110 | 23 of 109 | 219 | NCT01265498 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007027/comparisons